Bimekizumab

Bimekizumab, sold under the brand name Bimzelx, is a humanized anti-IL17A, anti-IL-17F, and anti-IL17AF monoclonal antibody[3][4] that is used to treat plaque psoriasis.[3]

Bimekizumab
Monoclonal antibody
TypeWhole antibody
SourceHumanized
TargetIL17A, IL17F, IL17AF
Clinical data
Trade namesBimzelx
License data
Pregnancy
category
ATC code
Legal status
Legal status
Identifiers
CAS Number
UNII
KEGG

The most common side effects include upper respiratory tract infections (nose and throat infection) and oral candidiasis (thrush, a fungal infection in the mouth or throat).[3]

Bimekizumab was approved for medical use in the European Union in August 2021.[3][5]

Medical uses

Bimekizumab is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy.[3]

History

This drug is being developed by Belgian pharmaceutical company UCB. Phase III trials have demonstrated that bimekizumab is superior to not only adalimumab[6] but also secukinumab[7] and ustekinumab[8] for the treatment of plaque psoriasis.

Society and culture

Names

Bimekizumab is the international nonproprietary name (INN).[9]

References
  1. "Bimzelx APMDS". Therapeutic Goods Administration (TGA). 7 April 2022. Archived from the original on 24 April 2022. Retrieved 24 April 2022.
  2. "Bimzelx Product information". Health Canada. 25 April 2012. Archived from the original on 29 June 2022. Retrieved 29 June 2022.
  3. "Bimzelx EPAR". European Medicines Agency (EMA). 23 June 2021. Archived from the original on 25 August 2021. Retrieved 24 August 2021. Text was copied from this source which is © European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
  4. Lim SY, Oon HH (2019-05-13). "Systematic review of immunomodulatory therapies for hidradenitis suppurativa". Biologics: Targets and Therapy. 13: 53–78. doi:10.2147/BTT.S199862. PMC 6526329. PMID 31190730.
  5. "UCB Announces European Commission Approval of Bimzelx (bimekizumab) for the Treatment of Adults with Moderate to Severe Plaque Psoriasis". UCB (Press release). 24 August 2021. Archived from the original on 25 August 2021. Retrieved 24 August 2021.
  6. Warren, Richard B.; Blauvelt, Andrew; Bagel, Jerry; Papp, Kim A.; Yamauchi, Paul; Armstrong, April; et al. (July 2021). "Bimekizumab versus Adalimumab in Plaque Psoriasis". New England Journal of Medicine. 385 (2): 130–141. doi:10.1056/NEJMoa2102388. PMID 33891379. S2CID 233372177.
  7. Reich, Kristian; Warren, Richard B.; Lebwohl, Mark; Gooderham, Melinda; Strober, Bruce; Langley, Richard G.; et al. (July 2021). "Bimekizumab versus Secukinumab in Plaque Psoriasis". New England Journal of Medicine. 385 (2): 142–152. doi:10.1056/NEJMoa2102383. PMID 33891380. S2CID 233370455.
  8. Reich, Kristian; Papp, Kim A.; Blauvelt, Andrew; Langley, Richard G.; Armstrong, April; Warren, Richard B.; et al. (February 2021). "Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial". The Lancet. 397 (10273): 487–498. doi:10.1016/S0140-6736(21)00125-2. PMID 33549193. S2CID 231809826.
  9. World Health Organization (2014). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 72". WHO Drug Information. 28 (3). hdl:10665/331112.

Further reading
  • Reis J, Vender R, Torres T (August 2019). "Bimekizumab: The First Dual Inhibitor of Interleukin (IL)-17A and IL-17F for the Treatment of Psoriatic Disease and Ankylosing Spondylitis". BioDrugs. 33 (4): 391–9. doi:10.1007/s40259-019-00361-6. PMID 31172372. S2CID 174812750.
  • "Bimekizumab". Drug Information Portal. U.S. National Library of Medicine.


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.